Tudor Investment Corp ET AL Takes Position in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Tudor Investment Corp established a new position in Amneal Pharmaceuticals (NASDAQ: AMRX) in Q3 by purchasing 92,010 shares worth about $921,000.
• Several other institutions also added to their stakes—Allspring bought 1,135,799 shares (a 1,440% increase), BlackBarn now owns 3,446,570 shares, and overall institutional ownership stands at 31.82%.
• AMRX trades around $11.95 with a $3.76 billion market cap and a P/E of 51.96; analysts have an average rating of Buy with a $14.20 consensus price target and recent topside targets as high as $17.00.

Tudor Investment Corp ET AL purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 92,010 shares of the company's stock, valued at approximately $921,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackBarn Capital Partners LP increased its holdings in Amneal Pharmaceuticals by 19.6% during the 2nd quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company's stock worth $27,883,000 after purchasing an additional 564,916 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Amneal Pharmaceuticals by 22.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,332,366 shares of the company's stock valued at $10,779,000 after buying an additional 240,676 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Amneal Pharmaceuticals by 1,440.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company's stock worth $11,790,000 after buying an additional 1,062,045 shares in the last quarter. AustralianSuper Pty Ltd acquired a new stake in shares of Amneal Pharmaceuticals during the third quarter worth approximately $3,238,000. Finally, Walleye Capital LLC increased its stake in shares of Amneal Pharmaceuticals by 26.9% in the second quarter. Walleye Capital LLC now owns 708,946 shares of the company's stock worth $5,735,000 after buying an additional 150,104 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ AMRX opened at $11.95 on Tuesday. The company has a market capitalization of $3.76 billion, a price-to-earnings ratio of 51.96 and a beta of 1.34. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $15.42. The business has a 50 day simple moving average of $13.56 and a 200-day simple moving average of $12.20.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Barclays began coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an "overweight" rating and a $15.00 price target on the stock. Truist Financial boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Weiss Ratings restated a "hold (c)" rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Zacks Research raised shares of Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $14.20.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.